ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "prevention"

  • Abstract Number: 0208 • ACR Convergence 2023

    Pneumocystis Jirovecii Pneumonia (PJP) Prophylaxis (PPX), Investigating the Practice Patterns of Providers for Patients on Chronic, High-Dose Immunosuppression in a Rural Integrated Health System

    Angela Bobak1, Emely Pimentel1, Jordan Jackson2, Celia Gray3, Hema Srinivasan3, Andrea Berger3 and David Bulbin3, 1Geisinger Medical Center Internal Medicine Residency, Danville, PA, 2Geisinger Medical Center Medicine-Pediatrics Residency, Danville, PA, 3Geisinger Health System, Danville, PA

    Background/Purpose: PJP is an opportunistic fungus causing significant morbidity and mortality in immunocompromised patients.  Guidelines describe PJP PPX indications among non-HIV infected individuals with cancer…
  • Abstract Number: 1387 • ACR Convergence 2023

    Power Doppler Musculoskeletal Abnormalities in Patients with Psoriasis at High Risk of Progression to Psoriatic Arthritis

    Rebecca Haberman1, Sarah Moussavi1, Yan Zhang1, Sydney Catron1, Jonathan Samuels2, Rebecca Blank3, Michael Toprover4, Jiyuan Hu1, Cinty Gong5, Vincent Piguet6, Francisco Tausk7, Jensen Yeung8, Andrea Neimann1, Wayne Gulliver9, Joseph Merola10, Alexis R Ogdie11, Proton Rahman12, Soumya Chakravarty13, Ralf Thiele14, Lihi Eder15, Christopher T Ritchlin16 and Jose Scher17, 1NYU Grossman School of Medicine, New York, NY, 2NYU Langone, Rye Brook, NY, 3New York University, New York, NY, 4New York University Langone Health, New York, NY, 5Immunology, Janssen Scientific Affairs, LLC, Horsham, PA, USA, Raritan, NJ, 6Women's College Hospital, Toronto, ON, Canada, 7University of Rochester Medical Center, Rochester, NY, 8University of Toronto and Women’s College Hospital, Toronto, ON, Canada, 9Memorial University of Newfoundland, St. John's, NL, Canada, 10Harvard Medical School, Brigham and Women's Hospital, Newton, MA, 11University of Pennsylvania, Philadelphia, PA, 12Craig Dobbin Research Institute, Memorial University, St. John's, NL, Canada, 13Immunology, Janssen Scientific Affairs, LLC / Division of Rheumatology, Drexel University College of Medicine, Villanova, PA, 14University of Rochester, Pittsford, NY, 15Women’s College Research Institute, Division of Rheumatology, University of Toronto, Toronto, ON, Canada, 16University of Rochester Medical School, Allergy, Immunology & Rheumatology Division, Canandaigua, NY, 17New York University School of Medicine, New York, NY

    Background/Purpose: Psoriatic arthritis (PsA) is an immune-mediated disease associated with skin psoriasis that, if untreated, can lead to joint destruction. Up to 30% of patients…
  • Abstract Number: 2585 • ACR Convergence 2023

    Cytokine and Chemokine Elevations in ACPA+ Individuals Suggest Possible Viral, Mucosal and/or Innate Responses Are Related to the Transition to Future Clinical RA

    Daniel Carlson1, Charles Carpenter2, Salina Goff1, Jennifer Seifert1, LauraKay Moss1, Marie Feser1, Jane Buckner3, William H. Robinson4, Jessica Kirschmann4, Gary Firestein5, Michael Holer1 and Kevin Deane1, 1University of Colorado Anschutz Medical Campus, Aurora, CO, 2Colorado School of Public Health, Aurora, CO, 3Benaroya Research Institute at Virginia Mason, Seattle, WA, 4Stanford University, Palo Alto, CA, 5University of California San Diego, San Diego, CA

    Background/Purpose: Rheumatoid arthritis (RA) has a ‘pre-RA’ period definable as elevations of antibodies to citrullinated protein antibodies (ACPA) before clinically-apparent inflammatory arthritis (i.e. Clinical RA).…
  • Abstract Number: 0209 • ACR Convergence 2023

    Safety of Bivalent SARS-CoV-2 Vaccines as a Second Booster Dose in Arthritis Patients on Immunosuppressive Therapies

    Hilde Ørbo1, Ingrid Jyssum1, Anne Therese Tveter1, Ingrid Christensen1, Joseph Sexton1, Kristin Hammersbøen Bjørlykke2, Grete B. Kro3, Tore Kvien1, Gunnveig Grødeland4, Ludvig A. Munthe5, Siri Mjaaland6, John Torgils Vaage5, Espen Haavardsholm1, Kristin Kaasen Jørgensen2, Sella Provan7, Silje Watterdal Syversen1 and Guro Goll1, 1Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, 2Department of Gastroenterology, Akershus University Hospital, Oslo, Norway, 3Department of Microbiology, Oslo University Hospital, Oslo, Norway, 4Department of Immunology, Oslo University Hospital, Oslo, Norway, 5Department of Immunology, Oslo University Hospital, Oslo, Norway, 6Norwegian Institute of Public Health, Oslo, Norway, 7Diakonhjemmet Hospital, Oslo, Norway

    Background/Purpose: Safety and efficacy of updated bivalent vaccines, containing both the original vaccine variant of SARS-CoV-2 Spike and either Omicron variants BA.1 or BA.4/5, are…
  • Abstract Number: 1801 • ACR Convergence 2023

    Tixagevimab/Cilgavimab for the Prevention of COVID-19 in Vaccine-refractory Patients with Autoimmune Diseases: A Prospective Cohort Study

    Ioanna Minopoulou1, Koray Tascilar2, Giulia Corte1, Melek Yalcin Mutlu1, Katja Schmidt2, Daniela Bohr1, Fabian Hartmann2, Bernhard Manger2, Arnd Kleyer3, David Simon1, Thomas Harrer2, Georg Schett4 and Filippo Fagni1, 1Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg & Universitätsklinikum Erlangen, Department of Internal Medicine 3 - Rheumatology and Immunology / Deutsches Zentrum Immuntherapie, Erlangen, Germany, 2Department of Internal Medicine 3, Friedrich-Alexander University (FAU) Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, 3University Hospital Erlangen, Erlangen, Germany, 4Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Patients with immune-mediated inflammatory diseases (IMIDs) and particularly those treated with B-cell-depleting agents frequently fail to develop humoral responses to SARS-CoV-2 vaccinations and have…
  • Abstract Number: 0217 • ACR Convergence 2023

    Safety and Efficacy of Tixagevimab/Cilgavimab (Evusheld) in Autoimmune Inflammatory Rheumatic Disease Patients – a Prospective Multicenter Open-label Study

    Tali Eviatar1, Victoria Furer2, Ilana Kaufman3, David levartovsky2, Ofir Elalouf2, Devy Zisman4, Tal Gazitt5, Amir Haddad4, Muna Elias6, Joy Feld7, Alexandra Balbir-Gurman8, Yolanda Braun Moscovici9, Sara Pel10, sharon Nevo11, Daphna Paran2 and Ori Elkayam2, 1Tel Aviv Sourasky Medical center, Ramat Gan, Israel, 2Tel Aviv Medical Center, Tel Aviv, Israel, 3Tel Aviv Medical Center, Petah-Tikva, Israel, 4Carmel Medical Center, Haifa, Israel, 5Carmel Hospital, Haifa, Israel, 6rheumatology unit, Haifa, Israel, 7Carmel and Zvulun Medical Centre, Haifa, Israel, 8Rheumatology Institute, Rambam Health Care Campus and Rappaport Faculty of |Medicine, Technion, Haifa, Israel, 9Rambam Heath Care Campus, Haifa, Israel, 10Tel Aviv Medical Center, Modiin, Israel, 11Tel Aviv Sourasky Medical Center, Givataim, Israel

    Background/Purpose: Autoimmune inflammatory rheumatic disease (AIIRD) patients treated with rituximab (RTX) are at risk for severe COVID19 infection, and a blunted humoral response to SARS-CoV-2…
  • Abstract Number: 1848 • ACR Convergence 2023

    Demographic and Clinical Factors Associated with HPV Vaccination in Young Adults with Rheumatic Disease

    Caroline Siegel1, Lauren Robinson1, Deanna Jannat-Khah1, Avi Mikhaylov1, Nancy Pan1 and Lisa Sammaritano2, 1Hospital for Special Surgery, New York, NY, 2Hospital for Special Surgery, Weill Cornell Medicine, New York, NY

    Background/Purpose: The HPV vaccine is safe and immunogenic in RD patients but uptake is suboptimal. We aimed to evaluate factors associated with HPV vaccination in…
  • Abstract Number: 0219 • ACR Convergence 2023

    Safety and Efficacy of Pre-Exposure Prophylaxis with Tixagevimab/Cilgavimab (Evusheld) in Patients with Autoimmune Diseases and Renal Involvement Who Received Rituximab

    Savino Sciascia1, MARIA LETIZIA RILAT2, ROBERTA FENOGLIO2, SILVIA GRAZIETTA FODDAI3, MASSIMO RADIN3, IRENE CECCHI3, giacoma cinnirella2, paola crosasso2, maria gabriella guidetti2, ALICE BARINOTTI3, simone baldovino2, ELISA MENEGATTI4 and Dario Roccatello5, 1University of Turin, Torino, Italy, 2University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, San Giovanni Bosco Hub Hospital, Turin, Italy, 3University Center of Excellence on Nephrologic, Rheumatologic and Rare Diseases (ERK-Net, ERN-Reconnect and RITA-ERN Member) with Nephrology and Dialysis Unit and Center of Immuno-Rheumatology and Rare Diseases (CMID), Coordinating Center of the Interregional Network for Rare Diseases of Piedmont and Aosta Valley, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, 4School of Specialization of Clinical Pathology, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy, 5University of Torino, Torino, Italy

    Background/Purpose: Patients on B-cell depleting agents may have a suboptimal response to vaccination, placing them at a higher risk of contracting SARS-CoV-2 or suffering from…
  • Abstract Number: 1856 • ACR Convergence 2023

    Improving Recombinant Zoster Vaccination Rates in Patients Receiving Immunosuppressive Therapy in the Rheumatology Clinic at the Orlando VA Healthcare System – a Quality Improvement Project

    Kathlyn Camargo Macias1, Ravi Shahu Khal1, Ariail Schmitz2, Kathleen McCabe1, Taylor Kann1, Marilyn Mosquera3 and Ashwini Komarla4, 1University of Central Florida, Orlando, FL, 2University of Central Florida, St. Cloud, FL, 3University of Central Florida, Casselberry, FL, 4ORLANDO VAMC, Orlando, FL

    Background/Purpose: Herpes zoster is a painful rash that involves one to three adjacent dermatomes, secondary to reactivation of latent varicella-zoster virus (VZV). About 95 %…
  • Abstract Number: 0616 • ACR Convergence 2023

    Does Systemic Sclerosis Affect the Interpretation of Mammograms? A Retrospective Cohort Study

    Lea Meir1, Tegveer Sandhu2, Weiwei Chi2 and Gabriela Santiago2, 1Icahn School of Medicine, New York, NY, 2Icahn School of Medicine at Mount Sinai, New York, NY

    Background/Purpose: Systemic Sclerosis is an autoimmune disorder marked by thickened and hardened skin. Cutaneous cutis, the deposition of insoluble calcium salts in the skin and…
  • Abstract Number: 1895 • ACR Convergence 2023

    Comparative Analysis of Existing Tools in Assessing Cardiovascular Risk in Patients with Rheumatoid Arthritis: Exploring the Inadequacies

    Pritee Shrestha1, Peter Larsen1 and Pablo Weilg Espejo2, 1Mercy One North Iowa Medical Center, Mason City, IA, 2Boston Medical Center, Chelsea, MA

    Background/Purpose: Patients with Rheumatoid Arthritis (RA) are at increased risk of cardiovascular disease (CVD). Despite multiple CVD risk tools available, reliability to RA population is…
  • Abstract Number: 055 • 2023 Pediatric Rheumatology Symposium

    COVID-19 Vaccination in Children with Rheumatic Diseases: Results of a CARRA-wide Survey

    Beth Rutstein1, Merav Heshin Bekenstein2, Maria Schletzbaum3, Nora Singer4, Rebecca Sadun5, Melanie Kohlheim6, Vincent Del Gaizo7, Kelly Wise8, Melica Nikahd9, Guy Brock9, Monica Ardura8, Vidya Sivaraman10 and For the CARRA Investigators11, 1Children's Hospital of Philadelphia, Philadelphia, PA, 2Tel Aviv Medical Center, Tel Aviv, Israel, 3Medical College of Wisconsin, Milwaukee, WI, 4Metro Health, Cleveland, OH, 5Duke University, Durham, NC, 6None, Columbus, OH, 7CARRA, Washington, DC, 8Nationwide Children's Hospital, Columbus, OH, 9The Ohio State University, Columbus, OH, 10Nationwide Children's Hospital/ The Ohio State University, Columbus, OH, 11Duke University Medical Center, Durham, NC

    Background/Purpose: Children receiving immunosuppressive therapies (IST) have a higher risk of hospitalization from COVID-19. COVID-19 vaccines significantly reduce the likelihood of severe disease or death.…
  • Abstract Number: L08 • ACR Convergence 2022

    Breakthrough Acute COVID-19 Infection During the US Omicron Surge Following Administration of Tixagevimab/Cilgavimab in Immunocompromised Patients with Rheumatologic Disorders

    Christopher Podgorski1 and Deborah Parks2, 1BJC/Washington University Consortium, St. Louis, MO, 2Washington University/B-JH/SLCH Consortium, St. Louis, MO

    Background/Purpose: Treatment with Tixagevimab/Cilgavimab 150/150 mg was authorized by the FDA on 12/8/21 under an Emergency Use Authorization as pre-exposure prophylaxis against COVID-19 infection. The…
  • Abstract Number: L16 • ACR Convergence 2022

    Innovative Anti-pneumococcal Vaccine Strategies versus Standard Vaccination Regimen in Patients with ANCA-associated Vasculitides Receiving Rituximab Therapy: A Multicenter Randomized Controlled Trial (PNEUMOVAS)

    Benjamin Terrier1, Laura Richert2, Grégory Pugnet3, Olivier Aumaitre4, Olivier Moranne5, Elisabeth Diot6, Alexandre Karras7, Fabrice Bonnet8, Claire De Moreuil9, Eric Hachulla10, Thomas Le Gallou11, Céline Lebas10, Francois Maurier12, Cédric Rafat7, Maxime Samson13, Jean-Francois Augusto14, Grégoire Couvrat-Devergne15, Cécile Janssen16, Thierry Martin17, Thomas Quemeneur18, Pierre-Louis Caron19, Cécile-Audrey Durel20, Khalil El Karoui7, Aurélie Grados21, Mathieu Puyade22, Virginie Rieu4, Yurdagul Uzunhan23, Jean-Francois Viallard8, Xavier Puéchal7, Loic Guillevin7, Noémie Huchet8, Hendy Abdoul7, Carine Bellera8, Frédéric Batteux7 and Odile Launay7, 1Cochin Hospital, Paris, France, 2EUCLID, Bordeaux, France, 3CHU, Toulouse, France, 4CHU, Clermont-Ferrand, France, 5CHU, Nimes, France, 6CHU, Tours, France, 7CHU, Paris, France, 8CHU, Bordeaux, France, 9CHU, Brest, France, 10CHU, Lille, France, 11CHU, Rennes, France, 12CH, Metz, France, 13CHU, Dijon, France, 14CHU, Angers, France, 15CH, La Roche sur Yon, France, 16CH, Annecy, France, 17CHU, Strasbourg, France, 18CH, Valenciennes, France, 19CHU, Grenoble, France, 20CHU, Lyon, France, 21CH, Niot, France, 22CHU, Poitiers, France, 23CHU, Bobigny, France

    Background/Purpose: Patients receiving glucocorticoids plus rituximab (RTX) show an increased risk of infection, especially invasive pneumococcal infections. Vaccine responses to influenza, Streptococcus pneumoniae and SARS-CoV-2…
  • Abstract Number: 0939 • ACR Convergence 2022

    Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology

    J. Patricia Dhar1, Heather Walline2, Lamia Fathallah3, Susanna Szpunar4, Louis Saravolatz5, Gil Mor6 and Thomas Carey7, 1Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, 2University of Michigan, Ann Arbor, MI, 3Ascension St.John Hospital, Detroit, MI, 4Ascension St. John Hospital, Grosse Pointe Woods, MI, 5Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, 6Wayne State University and C.S. Mott Center for Human Growth and Development., Detroit, MI, 7University of Michigan School of Medicine, Ann Arbor, MI

    Background/Purpose: A health disparity exists for AA women with SLE who have increased morbidity & mortality from both cervical cancer & SLE. Current cervical cancer…
  • « Previous Page
  • 1
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • …
  • 12
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology